Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px
Document › Details

Protectimmun GmbH. (9/28/15). "Press Release: Protectimmun Teams Up With Johnson & Johnson Innovation and Imperial College under a Research Funding Agreement". Gelsenkirchen.

Organisations Organisation Protectimmun GmbH
  Organisation 2 Johnson & Johnson Innovation Centre London
  Group Johnson & Johnson (JnJ) (Group)
Products Product preclinical research
  Product 2 asthma drugs
Index term Index term JnJ–Protectimmun: asthma drug, 201509 collab research JnJ Innovation funding preclinical study at Imperial College Protectimmune lead candidate
Person Person Kauth, Marion (Protectimmun GmbH 200703 Managing Director + co-founder)
     


Protectimmun GmbH, a biopharmaceutical R&D company, announced today that it has entered into a research funding agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Imperial College, London. The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research conducted at Imperial College by Prof Clare Lloyd with one of Protectimmun’s lead candidates in a proof-of-concept disease model of allergic asthma developed by Prof Lloyd.

“We are very pleased about the opportunity to strengthen and expand our preclinical data package for this program through this collaboration”, said Marion Kauth, Ph.D., co-founder and Chief Executive Officer of Protectimmun. “This agreement strongly supports our ambition to pave the way for a disruptive first-in-class approach to combat allergic asthma and hay fever.”

Protectimmun focusses on new approaches in the prevention and therapy of allergic and chronic inflammatory diseases. Its innovative concept for product development is based on the identification of natural substances and bacteria with immunomodulatory properties from particular farm environments which are selectively transferred into pharmaceutical applications. Promising candidates that were successfully tested in proof-of-concept animal models of asthma are currently in mid- to late-stage preclinical development.

”It is impressive to see Johnson & Johnson Innovation’s strong commitment to creating new types of early-stage R&D collaborations to foster innovative healthcare solutions”, added Marcus Peters, PhD, board member of Protectimmun.


Contact

Protectimmun GmbH
Marion Kauth, PhD, CEO
+49 209 389 66 556
info@protectimmun.de
http://www.protectimmun.de

   
Record changed: 2017-04-02

Advertisement

Picture [LSF] Life-Sciences-France.com – The Business Web Portal 600x80px

More documents for Protectimmun GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px




» top